the aid library

LIST OPTIONS

Filter

2351

Sort by:

Direction:

Download (1389)

View PDF (3026)

Tuberculosis. Practical guide for clinicians, nurses, laboratory technicians and medical auxiliaries

Médecins sans Frontières MSF (2022) C2

This Tuberculosis guide has been developed jointly by Médecins Sans Frontières and Partners In Health. It aims at providing useful information to the clinicians and health staff for the comprehensive management of tuberculosis. Forms of susceptible and resistant tuberculosis, tuberculosis in child... more

Download (1161)

View PDF (3036)

Kenya : Management of Severe Malaria
recommended

World Health Organization WHO (2012) C_WHO

This Handbook, an updated edition of the Management of Severe Malaria, provides new and revised practical guidance on the diagnosis and management of severe malaria.

Download (804)

View PDF (1853)

Guidelines for treatment of tuberculosis

World Health Organization (2010) C_WHO

4th edition. This is fourth edition of Treatment of tuberculosis: guidelines, adhering fully to the new WHO process for evidence-based guidelines. Several important recommendations are being promoted in this new edition

Download (7971)

View PDF (5650)

Practical Guidelines for Infection Control in Health Care Facilities
recommended

Manju Vatsa, Duangvadee Sungkhobol, Sudarshan Kumari, et al. WHO Western Pacific, Manila, and WHO South-East Asia, New Delhi (2004)

Download (1159)

View PDF (3433)

Control of Epidemic Meningococcal Disease

World Health Organization (1998)

WHO practical guidelines. 2nd edition

Download (6235)

View PDF (5109)

Leprosy For Medical Practitioners and Paramedical Workers
recommended

Yawalker, S. (2009) C1

Download (1135)

View PDF (2683)

Tuberculose. Guide pratique à l’usage des médecins, infirmiers, techniciens de laboratoire et auxiliaires de santé
recommended

Mèdecines sans Frontières MSF (2022) C3

Download (215)

View PDF (635)

Lymphatic Filariasis Increases Tissue Compressibility and Extracellular Fluid in Lower Limbs of Asymptomatic Young People in Central Myanmar

Douglass, Janet; Graves, Patricia; Lindsay, Daniel et al. (2017) CC

Tropical Medicine and Infectious Disease 2017, 2(4), 50
This is a cross-sectional analysis of baseline data in a longitudinal study on asymptomatic, LF antigen-positive and -negative young people in Myanmar. Rapid field screening was used to identify antigen-positive cases and a group of antige... more

Download (1428)

View PDF (3428)

Guidelines for Management of Malaria in Zimbabwe

Ministry of Health and Child Welfare, Zimbabwe (2009) C1

DIAGNOSIS, MANAGEMENT OF UNCOMPLICATED AND SEVERE MALARIA

Download (693)

View PDF (1550)

Ministerial Guidelines on Viral Hemorrhagic Fever Case Management
recommended

Ministry of Health, Rwanda (2014) C1

Download (1014)

View PDF (2623)

Background document: the diagnosis, treatment, and prevention of typhoid fever

World Health Organization (2003) C_WHO

Download (823)

View PDF (1600)

Introduction to the Core Curriculum on Tuberculosis: What the Clinician Should Know

Center for Disease Control and Prevention (2013)

Sixth Edition

Download (241)

View PDF (180)

Guidelines for the use of antibiotics in production animals: Cattle, pigs, sheep and goats

The Swedish Veterinary Association SVS (2017) C2

In 1998 the Swedish Veterinary Association decided to adopt a general policy for the use of antibiotics in animals. Since then specifi c policies for the use of antibiotics in dogs and cats have been adopted and in 2011 Guidelines for the use of Antibiotics in Production animals – Cattle and Pigs,... more

Download (79)

View PDF (908)

Effectiveness of Education and an Antibiotic-Control Program in a Tertiary Care Hospital in Thailand

Apisarnthanarak A.,S. Danchaivijitr,T. Khawcharoenporn, et al. (2006) C2

Overuse of antimicrobial agents occurs globally in both community and hospital settings. Misuse of antibiotics can lead to a variety of adverse outcomes, including the development of antimicrobial resistanceand increased cost of hospitalization. This issuehas been particularly problematic in de... more

Download (106)

View PDF (137)

ECDC/EFSA/EMA first joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals

European Centers for Disease Control and Prevention ECDC (2015) C2

The ECDC, the EFSA and the EMA have for the first time jointly explored associations between consumption of antimicrobials in humans and food-producing animals, and antimicrobial resistance in bacteria from humans and food-producing animals, using 2011 and 2012 data currently available from their re... more

Download (97)

View PDF (146)

COVID Reference 2020.3 DEU
recommended

Kamps, B.S.; and C. Hoffmann (2020) CC

Download (122)

View PDF (125)

COVID-19: Chloroquine and hydroxychloroquine research

World Health Organization WHO (2020) C_WHO

This document updates the earlier version published in April 2020. In recent weeks, information on the potential use of chloroquine or hydroxychloroquine for the treatment of people with COVID-19 has been disseminated in academic journals and public media. Although there are now ongoing clinical tri... more

Download (165)

View PDF (184)

Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection

World Health Organization WHO (2018) C_WHO

Download (199)

View PDF (238)

Guidance on mainstreaming biodiversity for nutrition and health

World Health Organization WHO (2020) C_WHO

This report aims to support countries in the necessary transition toward healthier, more sustainable diets by integrating biodiversity in food-based interventions to support nutrition and health. It is intended to help guide decision-makers in the health, nutrition and other sectors, to: Consider... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Kenya : Management of Severe Malaria recommended

Practical Guidelines for Infection Control in Health Care Facilities recommended

Leprosy For Medical Practitioners and Paramedical Workers recommended

Tuberculose. Guide pratique à l’usage des médecins, infirmiers, techniciens de laboratoire et auxiliaires de santé recommended

Ministerial Guidelines on Viral Hemorrhagic Fever Case Management recommended

COVID Reference 2020.3 DEU recommended